5 analysts have expressed a variety of opinions on Arvinas (NASDAQ:ARVN) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $71.4, a high estimate of $88.00, and a low estimate of $40.00. Highlighting a 9.04% decrease, the current average has fallen from the previous average price target of $78.50.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive Arvinas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Arvinas's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Arvinas analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Arvinas

Understanding the Numbers: Arvinas's Finances

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Arvinas displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 195.95%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Arvinas's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -48.05%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Arvinas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.3%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Arvinas's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.02%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Arvinas's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Significance of Analyst Ratings Explained

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.